{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T20:06:20Z","timestamp":1784577980384,"version":"3.55.0"},"reference-count":44,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:00:00Z","timestamp":1776816000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["kireports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International Reports"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.ekir.2026.106568","type":"journal-article","created":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T07:02:16Z","timestamp":1778050936000},"page":"106568","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Immunofluorescence Patterns in IgAN are Associated With Active, Necrotizing Lesions"],"prefix":"10.1016","volume":"11","author":[{"given":"Abdul A.","family":"Abou-Watfa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian G.","family":"Scurt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sascha T.","family":"Bender","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thorsten","family":"Wiech","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hermann-Josef","family":"Gr\u00f6ne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter R.","family":"Mertens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ekir.2026.106568_bib1","first-page":"694","article-title":"Intercapillary deposits of IgA-IgG","volume":"74","author":"Berger","year":"1968","journal-title":"J Urol N\u00e9phrol (Paris)"},{"key":"10.1016\/j.ekir.2026.106568_bib2","doi-asserted-by":"crossref","first-page":"54","DOI":"10.3390\/medicina60010054","article-title":"IgA nephropathy: beyond the half-century","volume":"60","author":"Shimizu","year":"2024","journal-title":"Medicina"},{"key":"10.1016\/j.ekir.2026.106568_bib3","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41581-024-00885-3","article-title":"The pathogenesis of IgA nephropathy and implications for treatment","volume":"21","author":"Cheung","year":"2025","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.ekir.2026.106568_bib4","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1038\/ki.2009.243","article-title":"The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification","volume":"76","author":"Cattran","year":"2009","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2026.106568_bib5","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1038\/ki.2010.43","article-title":"The Oxford IgA nephropathy clinicopathological classification is valid for children as well as adults","volume":"77","author":"Coppo","year":"2010","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2026.106568_bib6","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1053\/j.ajkd.2021.01.024","article-title":"IgA nephropathy: core curriculum 2021","volume":"78","author":"Pattrapornpisut","year":"2021","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2026.106568_bib7","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s12882-024-03577-z","article-title":"Histological reappraisal of IgA nephropathy: the role of glomerular pattern of injury and mesangial complement deposition","volume":"25","author":"Obri\u015fc\u0103","year":"2024","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.ekir.2026.106568_bib8","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/s41572-023-00476-9","article-title":"IgA nephropathy","volume":"9","author":"Stamellou","year":"2023","journal-title":"Nat Rev Dis Prim"},{"key":"10.1016\/j.ekir.2026.106568_bib9","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1681\/ASN.0000000000000242","article-title":"Treatment of IgA nephropathy: a rapidly evolving field","volume":"35","author":"El Karoui","year":"2024","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2026.106568_bib10","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.kint.2023.11.003","article-title":"Targeted-release budesonide modifies key pathogenic biomarkers in immunoglobulin A nephropathy: insights from the NEFIGAN trial","volume":"105","author":"Wimbury","year":"2024","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2026.106568_bib11","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/S0140-6736(23)01554-4","article-title":"Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial","volume":"402","author":"Lafayette","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.ekir.2026.106568_bib12","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa2305635","article-title":"A Phase 2 trial of Sibeprenlimab in patients with IgA nephropathy","volume":"390","author":"Mathur","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2026.106568_bib13","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/j.kint.2024.03.012","article-title":"A phase 2b, randomized, double-blind, placebo-controlled, clinical trial of atacicept for treatment of IgA nephropathy","volume":"105","author":"Lafayette","year":"2024","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2026.106568_bib14","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.kint.2023.09.027","article-title":"Results of a randomized double-blind placebo-controlled Phase 2 study propose iptacopan as an alternative complement pathway inhibitor for IgA nephropathy","volume":"105","author":"Zhang","year":"2024","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2026.106568_bib15","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/j.ekir.2023.01.041","article-title":"Targeting the alternative complement pathway with iptacopan to treat IgA nephropathy: design and rationale of the APPLAUSE-IgAN study","volume":"8","author":"Rizk","year":"2023","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.ekir.2026.106568_bib16","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2021.05.021","article-title":"KDIGO 2021 clinical practice guideline for the management of glomerular diseases","volume":"100","author":"Rovin","year":"2021","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2026.106568_bib17","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2026.106568_bib18","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.kint.2021.03.033","article-title":"A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy","volume":"100","author":"Wheeler","year":"2021","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2026.106568_bib19","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"Herrington","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2026.106568_bib20","article-title":"Long-term outcomes of patients with IgA nephropathy in the German CKD cohort","volume":"17","author":"Stamellou","year":"2024","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.ekir.2026.106568_bib21","doi-asserted-by":"crossref","DOI":"10.1093\/ndt\/gfae069.1318","article-title":"# 1993 Analysis of the characteristics of IgA nephropathy patients using real-world data from five European countries","volume":"39","author":"Csomor","year":"2024","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2026.106568_bib22","doi-asserted-by":"crossref","DOI":"10.1080\/0886022X.2023.2182133","article-title":"Mitochondrial DNA copy number in peripheral blood of IgA nephropathy: a cross-sectional study","volume":"45","author":"Liu","year":"2023","journal-title":"Ren Fail"},{"key":"10.1016\/j.ekir.2026.106568_bib23","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1038\/s41598-024-52581-8","article-title":"Glomerular spatial transcriptomics of IgA nephropathy according to the presence of mesangial proliferation","volume":"14","author":"Park","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.ekir.2026.106568_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2024.110232","article-title":"Complement system is overactivated in patients with IgA nephropathy after COVID-19","volume":"263","author":"Guo","year":"2024","journal-title":"Clin Immunol"},{"key":"10.1016\/j.ekir.2026.106568_bib25","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1186\/s12882-021-02560-2","article-title":"The relationship between glomerular IgG staining and poor prognostic findings in patients with IgA nephropathy: the data from TSN-GOLD working group","volume":"22","author":"Turgutalp","year":"2021","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.ekir.2026.106568_bib26","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1080\/0886022X.2020.1811120","article-title":"IgG deposits in the mesangium and capillary loops predict poor renal outcome in patients with IgA nephropathy: a single-center retrospective study","volume":"42","author":"Peng","year":"2020","journal-title":"Ren Fail"},{"key":"10.1016\/j.ekir.2026.106568_bib27","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s10157-012-0660-0","article-title":"Clinical significance of IgG deposition in the glomerular mesangial area in patients with IgA nephropathy","volume":"17","author":"Wada","year":"2013","journal-title":"Clin Exp Nephrol"},{"key":"10.1016\/j.ekir.2026.106568_bib28","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0190967","article-title":"Serum galactose-deficient-IgA1 and IgG autoantibodies correlate in patients with IgA nephropathy","volume":"13","author":"Placzek","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.ekir.2026.106568_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e28509","article-title":"Glomerular IgG deposition predicts kidney disease progression in IgA nephropathy","volume":"10","author":"Xing","year":"2024","journal-title":"Heliyon"},{"key":"10.1016\/j.ekir.2026.106568_bib30","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1038\/modpathol.2016.77","article-title":"Glomerular IgG deposition predicts renal outcome in patients with IgA nephropathy","volume":"29","author":"Shin","year":"2016","journal-title":"Mod Pathol"},{"key":"10.1016\/j.ekir.2026.106568_bib31","first-page":"11","article-title":"IgG deposition in IgA nephropathy patients","volume":"2","author":"Nasri","year":"2013","journal-title":"J Ren Inj Prev"},{"key":"10.1016\/j.ekir.2026.106568_bib32","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1007\/s40265-023-01940-2","article-title":"Current understanding of complement proteins as therapeutic targets for the treatment of immunoglobulin A nephropathy","volume":"83","author":"Rajasekaran","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.ekir.2026.106568_bib33","article-title":"Molecular insight in intrarenal inflammation affecting four main types of cells in nephrons in IgA nephropathy","volume":"10","author":"Zhang","year":"2023","journal-title":"Front Med"},{"key":"10.1016\/j.ekir.2026.106568_bib34","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1056\/NEJMoa2410316","article-title":"Alternative complement pathway inhibition with iptacopan in IgA nephropathy","volume":"392","author":"Perkovic","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2026.106568_bib35","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1097\/TP.0000000000004640","article-title":"Evaluation of the modified Oxford Score in recurrent IgA nephropathy in North American kidney transplant recipients: the Banff recurrent glomerulonephritis working group report","volume":"107","author":"Alachkar","year":"2023","journal-title":"Transplantation"},{"key":"10.1016\/j.ekir.2026.106568_bib36","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1093\/ndt\/gfy302","article-title":"Is there long-term value of pathology scoring in immunoglobulin A nephropathy? A validation study of the Oxford Classification for IgA Nephropathy (VALIGA) update","volume":"35","author":"Coppo","year":"2020","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2026.106568_bib37","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.34067\/KID.0000000000000195","article-title":"Systematic review of the Oxford classification of IgA nephropathy: reproducibility and prognostic value","volume":"4","author":"Howie","year":"2023","journal-title":"Kidney360"},{"key":"10.1016\/j.ekir.2026.106568_bib38","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.2147\/IJGM.S313333","article-title":"The association of the Oxford classification score with longitudinal estimated glomerular filtration rate decline in patients with immunoglobulin A nephropathy: a mixed-method study","volume":"14","author":"Xu","year":"2021","journal-title":"Int J Gen Med"},{"key":"10.1016\/j.ekir.2026.106568_bib39","doi-asserted-by":"crossref","first-page":"947","DOI":"10.3390\/jcm13040947","article-title":"An update on current therapeutic options in IgA nephropathy","volume":"13","author":"Lim","year":"2024","journal-title":"J Clin Med"},{"key":"10.1016\/j.ekir.2026.106568_bib40","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1093\/ndt\/gfaf167","article-title":"Targeted therapeutic options based on the pathogenesis of IgA nephropathy","volume":"41","author":"Bo","year":"2025","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2026.106568_bib41","doi-asserted-by":"crossref","DOI":"10.3389\/fneph.2023.1346769","article-title":"The role of BAFF and APRIL in IgA nephropathy: pathogenic mechanisms and targeted therapies","volume":"3","author":"Cheung","year":"2024","journal-title":"Front Nephrol"},{"key":"10.1016\/j.ekir.2026.106568_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.semnephrol.2025.151573","article-title":"The rapidly changing treatment landscape of IgA nephropathy","volume":"44","author":"Cheung","year":"2024","journal-title":"Semin Nephrol"},{"key":"10.1016\/j.ekir.2026.106568_bib43","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1159\/000509997","article-title":"A personalized update on IgA nephropathy: a new vision and new future challenges","volume":"144","author":"Guti\u00e9rrez","year":"2020","journal-title":"Nephron"},{"key":"10.1016\/j.ekir.2026.106568_bib44","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1007\/s12325-025-03187-7","article-title":"An expert opinion on current and future treatment approaches in IgA nephropathy","volume":"42","author":"Glassock","year":"2025","journal-title":"Adv Ther"}],"container-title":["Kidney International Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024926028007?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024926028007?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T20:00:36Z","timestamp":1784577636000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468024926028007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":44,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S2468024926028007"],"URL":"https:\/\/doi.org\/10.1016\/j.ekir.2026.106568","relation":{},"ISSN":["2468-0249"],"issn-type":[{"value":"2468-0249","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunofluorescence Patterns in IgAN are Associated With Active, Necrotizing Lesions","name":"articletitle","label":"Article Title"},{"value":"Kidney International Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ekir.2026.106568","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of the International Society of Nephrology.","name":"copyright","label":"Copyright"}],"article-number":"106568"}}